Delayed
Japan Exchange
02:00:00 2024-05-02 am EDT
|
5-day change
|
1st Jan Change
|
2,441
JPY
|
+0.37%
|
|
-2.75%
|
-13.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
113,761
|
78,670
|
70,291
|
66,149
|
140,716
|
121,756
|
-
|
-
|
Enterprise Value (EV)
1 |
108,122
|
70,094
|
57,064
|
55,636
|
122,782
|
121,756
|
121,756
|
121,756
|
P/E ratio
|
610
x
|
62.4
x
|
65.2
x
|
170
x
|
16.7
x
|
17.1
x
|
11.7
x
|
8.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.3
x
|
8.05
x
|
5.54
x
|
3.8
x
|
5.41
x
|
3.07
x
|
2.42
x
|
1.74
x
|
EV / Revenue
|
15.3
x
|
8.05
x
|
5.54
x
|
3.8
x
|
5.41
x
|
3.07
x
|
2.42
x
|
1.74
x
|
EV / EBITDA
|
-
|
-
|
35
x
|
34.8
x
|
10.3
x
|
7.18
x
|
5.7
x
|
4.17
x
|
EV / FCF
|
447,876,054
x
|
70,429,323
x
|
187,435,950
x
|
-114,049,527
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
10.6
x
|
7.15
x
|
3.73
x
|
3.15
x
|
4.17
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
43,354
|
43,512
|
47,462
|
47,487
|
49,723
|
49,880
|
-
|
-
|
Reference price
2 |
2,624
|
1,808
|
1,481
|
1,393
|
2,830
|
2,441
|
2,441
|
2,441
|
Announcement Date
|
2/14/20
|
2/12/21
|
2/14/22
|
2/15/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
7,446
|
9,773
|
12,690
|
17,418
|
26,010
|
39,617
|
50,401
|
69,786
|
EBITDA
1 |
-
|
-
|
2,008
|
1,900
|
13,717
|
16,951
|
21,345
|
29,224
|
EBIT
1 |
1,302
|
1,869
|
1,624
|
1,377
|
13,108
|
16,337
|
20,725
|
28,597
|
Operating Margin
|
17.49%
|
19.12%
|
12.8%
|
7.91%
|
50.4%
|
41.24%
|
41.12%
|
40.98%
|
Earnings before Tax (EBT)
1 |
1,197
|
1,805
|
1,107
|
767
|
12,612
|
15,603
|
19,991
|
27,863
|
Net income
1 |
181
|
1,258
|
1,066
|
388
|
8,094
|
7,131
|
10,405
|
14,337
|
Net margin
|
2.43%
|
12.87%
|
8.4%
|
2.23%
|
31.12%
|
18%
|
20.64%
|
20.54%
|
EPS
2 |
4.300
|
28.96
|
22.72
|
8.190
|
169.5
|
143.0
|
209.0
|
288.0
|
Free Cash Flow
|
254
|
1,117
|
375
|
-580
|
-
|
-
|
-
|
-
|
FCF margin
|
3.41%
|
11.43%
|
2.96%
|
-3.33%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
18.68%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
140.33%
|
88.79%
|
35.18%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/20
|
2/12/21
|
2/14/22
|
2/15/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2023 S2
|
---|
Net sales
1 |
4,380
|
6,465
|
3,071
|
3,933
|
8,154
|
4,607
|
4,206
|
14,096
|
6,451
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
861
|
1,455
|
505
|
478
|
1,004
|
490
|
397
|
5,476
|
1,326
|
-
|
Operating Margin
|
19.66%
|
22.51%
|
16.44%
|
12.15%
|
12.31%
|
10.64%
|
9.44%
|
38.85%
|
20.55%
|
-
|
Earnings before Tax (EBT)
1 |
817
|
1,197
|
371
|
347
|
790
|
433
|
-64
|
5,117
|
1,259
|
-
|
Net income
1 |
244
|
941
|
353
|
351
|
676
|
400
|
-2
|
1,658
|
555
|
-
|
Net margin
|
5.57%
|
14.56%
|
11.49%
|
8.92%
|
8.29%
|
8.68%
|
-0.05%
|
11.76%
|
8.6%
|
-
|
EPS
2 |
5.630
|
20.30
|
7.390
|
7.400
|
14.25
|
8.420
|
-0.0600
|
34.93
|
11.68
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/14/20
|
8/13/21
|
11/15/21
|
5/16/22
|
8/15/22
|
11/14/22
|
5/15/23
|
8/14/23
|
11/14/23
|
2/14/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
5,639
|
8,576
|
13,227
|
10,513
|
17,934
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
254
|
1,117
|
375
|
-580
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
1.8%
|
11.6%
|
7.1%
|
2%
|
29.6%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
6.35%
|
6.84%
|
4.14%
|
2.39%
|
26.2%
|
-
|
-
|
-
|
Assets
1 |
2,851
|
18,386
|
25,766
|
16,239
|
30,901
|
-
|
-
|
-
|
Book Value Per Share
|
247.0
|
253.0
|
397.0
|
442.0
|
678.0
|
-
|
-
|
-
|
Cash Flow per Share
|
9.870
|
36.50
|
30.90
|
19.20
|
182.0
|
-
|
-
|
-
|
Capex
1 |
534
|
260
|
379
|
973
|
1,273
|
1,311
|
1,351
|
1,391
|
Capex / Sales
|
7.17%
|
2.66%
|
2.99%
|
5.59%
|
4.89%
|
3.31%
|
2.68%
|
1.99%
|
Announcement Date
|
2/14/20
|
2/12/21
|
2/14/22
|
2/15/23
|
2/14/24
|
-
|
-
|
-
|
Last Close Price
2,441
JPY Average target price
4,100
JPY Spread / Average Target +67.96% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.75% | 796M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|